BrainStorm Cell Therapeutics Inc. Will Host a Conference Call to Update
Shareholders on Upcoming Trial and Other Exciting Developments
NEW YORK & PETACH TIKVAH, Israel -- November 29, 2012
BrainStorm Cell Therapeutics Inc. (OTC:BCLI), a leading developer of adult
stem cell technologies and therapeutics, announced today that its senior
management will hold a conference call on Tuesday, December 11, 2012 at 8:00
a.m. EST in Hebrew and at 8:45 a.m. EST in English.
Dr. Adrian Harel, Chief Executive Officer, Mr. Chaim Lebovits, President, Ms.
Liat Sossover, Chief Financial Officer, and Prof. Eldad Melamed, PhD, Chief
Medical Advisor, will update on the upcoming trial and other exciting
Callers may participate in the conference call, in Hebrew at 08:00 a.m. EST
(03:00 p.m. Israel time), by dialing:
Callers may participate in the conference call, in English at 08:45 a.m. EST,
Callers are invited to ask relevant questions during the conference call.
Questions may also be pre-submitted to email@example.com prior to 7:00
a.m. EST on Thursday, December 6, 2012.
A recording of the conference will be available for download Monday, December
17, 2012 from the company’s website.
About BrainStorm Cell Therapeutics
BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the
development of adult stem cell therapeutic products derived from autologous
bone marrow cells and intended for the treatment of neurodegenerative
diseases. The Company holds the rights to develop and commercialize its
NurOwn™ technology through an exclusive, worldwide licensing agreement with
Ramot at Tel Aviv University Ltd., the technology transfer company of Tel-Aviv
University. For more information, visit the company’s website at
Safe Harbor Statement
Statements in this announcement other than historical data and information
constitute "forward-looking statements" and involve risks and uncertainties
that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ
materially from those stated or implied by such forward-looking statements.
Terms and phrases such as “may,” “should,” “would,” “could,” “will,” “expect,”
“likely,” “believe,” “plan,” “estimate,” “predict,” “potential,” and similar
terms and phrases are intended to identify these forward-looking statements.
The potential risks and uncertainties include, without limitation, risks
associated with BrainStorm's limited operating history, history of losses;
minimal working capital, dependence on its license to Ramot's technology;
ability to adequately protect the technology; dependence on key executives and
on its scientific consultants; ability to obtain required regulatory
approvals; and other factors detailed in BrainStorm's annual report on Form
10-K and quarterly reports on Form 10-Q available at http://www.sec.gov. These
factors should be considered carefully, and readers should not place undue
reliance on BrainStorm’s forward-looking statements. The forward-looking
statements contained in this press release are based on the beliefs,
expectations and opinions of management as of the date of this press release.
We do not assume any obligation to update forward-looking statements to
reflect actual results or assumptions if circumstances or management’s
beliefs, expectations or opinions should change, unless otherwise required by
law. Although we believe that the expectations reflected in the
forward-looking statements are reasonable, we cannot guarantee future results,
levels of activity, performance or achievements.
BrainStorm Cell Therapeutics Inc. (OTC: BCLI)
Adrian Harel, Ph.D., CEO
Press spacebar to pause and continue. Press esc to stop.